CTI BioPharma and its partner Baxter outlined positive Phase III data for their myelofibrosis drug pacritinib, which may help pave a way to position the therapy against Jakafi next year.
It was Johnson & Johnson's turn to take center stage at ASCO Saturday morning, fleshing out the promising data that it accumulated in a Phase II study of daratumumab for treatment-resistant multiple myeloma.
Bristol-Myers Squibb and rival Merck started off the big annual scientific meeting of ASCO with a bang, rolling out a slate of new studies spotlighting the growing body of evidence that their new immuno-oncology drugs will play a key role fighting a range of cancers.
Some analysts may be pooh-poohing a Pfizer buyout of GlaxoSmithKline, but some investors are hip to the idea.
AstraZeneca believes the brightest future for its top oncology prospect will come through collaboration, recruiting Eli Lilly to its growing ranks of partners with eyes on kicking off a combination cancer trial.
After posting a trio of Phase III victories, Amgen is plotting to submit the kidney dialysis drug AMG 416 for FDA review this year, charging forward with a successor to its own Sensipar.
Heron Therapeutics is gearing up for a third attempt at FDA approval for its chemotherapy-induced nausea and vomiting drug, posting a Phase III success after repeated delays.
Merck, working to scratch out a place in the market for next-generation hepatitis C cures, filed its new combination treatment for FDA approval in hopes of taking third place in a fast-crowding field.
In this week's EuroBiotech Report, Johnson & Johnson added another outpost to its burgeoning network of startup-scouting units. The J&J-Karolinska Institutet alliance kicked off a busy week for the Nordic region. And more.
Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.
What's a surefire way to build interdisciplinary communication and teamwork at a biotech company? Start a band, according to Momenta Pharmaceuticals CFO Rick Shea.
Wall Street's recent fervor over biotech companies has hardly been limited to local players, and the allure of handsome valuations and easy access to capital has brought more and more European drug developers across the Atlantic with hopes becoming the next big thing in a boom market.
Flush with a new, multibillion-dollar drug franchise, a booming Gilead is now hiring investigators for its fast-growing operations in Canada. The biotech is doubling down on its $100 million R&D investment in Alberta, Canada, with plans to expand on the new lab that opened this week at its Edmonton campus as it hires up to 170 more scientists for its R&D work.
A little more than a year after Forest Labs bought out Furiex and its experimental irritable bowel syndrome drug eluxadoline in a $1.5 billion deal, Brent Saunders and Forest-buyer Actavis have scored an FDA approval that should surprise no one. And the agency paired the approval with a green light for Valeant's Xifaxan (rifaximin) in IBS, another drug that's been changing hands lately in the frenzy of M&A deals that has been changing the face of the industry.
German institutions have claimed four of the top 5 spots on Thomson Reuters' list of the most influential pharma research centers. A clean sweep of the top four positions was only prevented by Gilead Sciences, which the report ranked second behind Goethe University Frankfurt Hospital.
Microbiome pioneer Seres Therapeutics is taking its promising lead therapy and the high expectations for an emerging field in biotech and heading to Wall Street, where it hopes to raise $100 million in an IPO that is likely to provide another litmus test of investors' appetite for new drug technologies.
Padlock Therapeutics, an Atlas Venture-seeded biotech startup, grabbed the rights to some potential drugs developed by GlaxoSmithKline, widening its arsenal of assets as it chases a novel approach to autoimmune disease.
Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash in a Nasdaq IPO.
Johnson & Johnson has established an outpost within Karolinska Institutet. The arrangement sees J&J set an innovation hub at the Swedish medical university, from which it will keep tabs on academic research breakthroughs and support the advance of such ideas into life science startups.